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Background—It is unknown whether the preferred 1-stent bifurcation stenting approach with stenting of the main vessel
(MV) and optional side branch stenting using drug-eluting stents should be finalized by a kissing balloon dilatation
(FKBD). Therefore, we compared strategies of MV stenting with and without FKBD.
Methods and Results—We randomized 477 patients with a bifurcation lesion to FKBD (n238) or no FKBD (n239) after MV
stenting. The primary end point was major adverse cardiac events: cardiac death, non–procedure-related index lesion myocardial
infarction, target lesion revascularization, or stent thrombosis within 6 months. The 6-month major adverse cardiac event rates were
2.1% and 2.5% (P1.00) in the FKBD and no-FKBD groups, respectively. Procedure and fluoroscopy times were longer and more
contrast media was needed in the FKBD group than in the no-FKBD group. Three hundred twenty-six patients had a quantitative
coronary assessment. At 8 months, the rate of binary (re)stenosis in the entire bifurcation lesion (MV and side branch) was 11.0%
versus 17.3% (P0.11), in the MV was 3.1% versus 2.5% (P0.68), and in the side branch was 7.9% versus 15.4% (P0.039)
in the FKBD versus no-FKBD groups, respectively. In patients with true bifurcation lesions, the side branch restenosis rate was 7.6%
versus 20.0% (P0.024) in the FKBD and no-FKBD groups, respectively.
Conclusions—MV stenting strategies with and without FKBD were associated with similar clinical outcomes. FKBD reduced
angiographic side branch (re)stenosis, especially in patients with true bifurcation lesions. The simple no-FKBD procedures resulted
in reduced use of contrast media and shorter procedure and fluoroscopy times. Long-term data on stent thrombosis are needed.
Clinical Trial Registration—URL: http://clinicaltrials.gov. Unique identifier: NCT00914199. (Circulation. 2011;123:79-86.)
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Bifurcation lesions represent 15% to 20% of percutane-ous coronary interventions (PCIs).1 PCI of bifurcation
lesions is challenging and associated with increased pro-
cedural costs, greater complication rates, and worse out-
comes compared with PCI of simple coronary lesions.2 The
rate of PCI-associated restenosis in the bare metal stent era
was reported to be up to 40%, and even worse in the side
branch (SB).3 The introduction of drug-eluting stents
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improved outcomes and resulted in low rates of main
vessel (MV) restenosis. However, SB ostial residual ste-
nosis and restenosis remained a problem. Bifurcation
treatment involves a number of steps: predilatation, im-
plantation of 1 or 2 stents, and postdilatation with single or
kissing balloon techniques. Several studies have compared
a 1-stent technique and a 2-stent technique using drug-
eluting stents for bifurcation lesions.4 –7 These studies
reported that 2-stent techniques did not offer any advan-
tage over stenting of the MV only but were associated with
increased use of contrast, longer procedure times, and
higher rates of procedure-related myocardial infarctions
(MIs).4,7 Therefore, the provisional SB stenting strategy
has emerged as the preferred bifurcation treatment strat-
egy. In the Nordic Bifurcation Study, the optional SB
stenting strategy resulted in a 20% SB restenosis rate at
follow-up. In that study, the SB was dilated through the
MV stent in one third of the patients.4 In 2-stent techniques
such as culotte and crush techniques, final kissing balloon
dilatation (FKBD) is currently considered mandatory.8
Whether FKBD will improve clinical and angiographic
outcomes after successful stenting of the MV remains
unknown. Therefore, the present study assessed, in a
randomized multicenter setting, whether routine FKBD
after successful stenting of the MV would improve out-
comes in patients with coronary artery bifurcation lesions.
Clinical Perspective on p 86
Methods
Patients and Study Design
The study, designed as a nonblinded randomized multicenter trial,
was conducted at 13 hospitals in Denmark, Finland, Latvia, Sweden,
and Norway. The patients were recruited from the general PCI
populations of the participating centers. From April 2007 through
October 2008, a total of 477 patients were enrolled, by estimate 20%
of eligible patients. A few patients (5%) were excluded from the
study because of impaired SB flow after MV stenting. A flow
diagram of the study is shown in Figure 1. National ethics commit-
tees approved the study protocol. All patients gave their written
informed consent before randomization.
Patients were eligible for randomization if they had either stable or
unstable angina pectoris or silent ischemia attributable to a de novo
coronary bifurcation lesion involving the MV. For inclusion, the MV
diameter had to be 2.5 mm and the SB had to be 2.25 mm by
visual estimate. No patients with SB lesion and no MV stenosis were
included. The exclusion criteria were ST-segment elevation MI
within 24 hours, life expectancy 1 year, serum creatinine
200 mol/L, and allergy to any of the drugs used (aspirin,
clopidogrel, and sirolimus).
Randomization
Patients were enrolled after successful stenting of the MV and with
preserved normal Thrombolysis in Myocardial Infarction blood flow
in the SB. The patients were allocated to treatment groups by use of
stratified block randomization with strata defined by site, gender, and
diabetes status (yes/no), each with separate computer-generated
treatment allocation sequences with permuted block sizes of 2, 4, and
6 in random order. Treatment allocation was properly concealed by
the use of an automated telephone allocation service provided by an
independent organization.
Stent Implantation
In the patients not receiving aspirin, 250 to 500 mg aspirin was
administered before the procedure. All patients received a loading
dose of 300 to 600 mg clopidogrel unless they were on long-term
treatment. In the catheterization laboratory, heparin or low-
molecular-weight heparin was administrated. Glycoprotein receptor
inhibitor and bivalirudin were used at the discretion of the operator.
After PCI, lifelong aspirin (75 mg/d) and clopidogrel (75 mg/d) for
12 months were recommended.
The operator was requested to avoid pretreatment (balloon dila-
tation) of MV segments that were not going to be covered by the
stent. The sirolimus-eluting Cypher Select (Cordis/Johnson &
Johnson, Miami Lakes, FL) coronary stent was used in the study.
The main treatment principles of the PCI procedure were as
follows: wiring of both the MV and SB, predilatation of the stenosed
areas of the MV and SB at the discretion of the operator, followed by
stenting of the MV and thus jailing of the SB wire. If there was
Thrombolysis in Myocardial Infarction grade 3 flow in the SB after
MV stenting, the patient was randomized to FKBD or no FKBD. If
the patient was randomized to the no-FKBD group, the procedure
was terminated even if a high-grade ostial SB stenosis was present.
In the FKBD group, the SB was rewired through the MV stent, and
simultaneous kissing balloon dilation was performed. There were no
specific recommendations for performing the simultaneous kissing
balloon dilatation. In case of SB Thrombolysis in Myocardial
Infarction flow less than grade 3 after FKBD, the SB was treated
with a stent.
If the study stent could not be delivered, another drug-eluting stent
or a bare metal stent was allowed. Different types of drug-eluting
stents in the same vessel were not allowed. Implantation of addi-
tional stents to cover the whole lesion or to cover a dissection was
allowed.
Cardiac Biomarkers and ECG
Creatine kinase-MB mass and cardiac troponin T or troponin I were
measured before intervention and 12 to 18 hours after intervention.
Estimate of eligibl
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Figure 1. Flow diagram of the Nordic-Baltic Bifurcation Study
III. FU indicates follow-up.
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Troponin T was used as the primary marker; creatine kinase-MB
mass or troponin I was measured only if troponin T was not
available. To avoid confounding by non–procedure-related marker
elevation, unstable patients were included in the biomarker analysis
only if preprocedure and postprocedure markers were normal. An
increase in biomarker values to 3 times the upper limit of normal
was considered significant. A 12-lead ECG was obtained before and
12 to 18 hours after the procedure.
Follow-Up
Information on death and other major adverse cardiac events
(MACEs) was obtained by phone contact at 1 month. Clinical
follow-up visit was performed at 6 months for primary end-point
registration. An 8-month control coronary angiography was sched-
uled at randomization for patients who consented. If patients in-
cluded in the angiographic substudy had clinical driven target lesion
revascularization (TLR) in the follow-up period, their event angio-
gram before PCI was used for their angiographic follow-up. No
patients were lost to follow-up.
Quantitative Coronary Angiography Analysis
at 8 Months
Coronary angiograms obtained at baseline, at the completion of the
stenting procedure, and at the 8-month follow-up were submitted to
the joint angiographic core laboratory (Aarhus University Hospital,
Skejby, Aarhus, Denmark, and Paul Stradins Clinical Hospital, Riga,
Latvia) and analyzed with the use of a computer-based system
dedicated to bifurcation analysis (QAngio XA version 7.2, Medis,
Leiden, the Netherlands). Quantitative coronary analysis of the
bifurcation lesion was obtained in 3 segments: the proximal MV
segment, the distal MV segment, and the SB. The MV edge segments
comprised the 5-mm margins to the stented segment. The first 5 mm
of the SB was used for analysis regardless of the treatment. The
analyses were not blinded.
Study End Points
The primary end point of the study was the clinical combined end
point of the MACEs: cardiac death, non–procedure-related index
lesion MI, stent thrombosis, or TLR by PCI or coronary artery
bypass surgery within 6 months. Secondary end points were (1) the
individual end points of total death, cardiac death, non–procedure-
related MI, or TLR; (2) procedure-related increase in biochemical
markers to 3 times the decision limit of MI (99th percentile) given
a coefficient of variation 10% of creatine kinase-MB mass,
troponin T, and/or troponin I; (3) the angiographic end point of
significant in-segment and in-stent restenosis (50% diameter ste-
nosis) of the MV and/or SB; and (4) Canadian Cardiovascular
Society (CCS) angina score 2. The clinical study end points were
adjudicated blindly by an independent end-point committee.
Definitions
Non–procedure-related MI was defined as a level of biochemical
markers exceeding the decision limit of MI (99th percentile) with at
least 1 of the following: ischemic symptoms, ECG changes indica-
tive of ischemia (ST-segment elevation or depression), or develop-
ment of pathological Q wave with no relation to a PCI procedure.
Definite stent thrombosis was defined according to the Academic
Research Consortium classification.9 TLR was defined as repeat revas-
cularization by PCI or surgery of the target lesion. Percent diameter
stenosis was defined as follows: (reference diameterminimal luminal
diameter)/reference diameter100. Restenosis was defined as a
minimum of 50% diameter stenosis at the 8-month angiographic
follow-up. Late lumen loss was defined as postprocedure minimal
luminal diameter minus minimal luminal diameter (in millimeters) at
the 8-month follow-up.
Statistical Analysis
We expected a MACE rate of 2% in the FKBD group and 8% in the
no-FKBD group. With an  of 5% and power of 80%, 206 patients
were needed in each group (2-sided 2 test) to demonstrate this
difference. By including 225 patients in each group, we accounted
for a possible dropout before follow-up, and we would expect 350
patients to schedule an angiographic follow-up.
Differences in categorical variables between the 2 groups were
analyzed with the 2 test or the Fisher exact test. Continuous
variables were analyzed with independent-sample t test and Mann-
Whitney U test, and time-to-event data were analyzed with the
Kaplan-Meier method and the log-rank test. All P values were 2
sided. The level of significance was 5%. The analysis was performed
on an intention-to-treat basis. All analyses were performed with
SPSS 13.0 (SPSS Inc, Chicago, IL).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Baseline Clinical Characteristics
Baseline clinical characteristics listed in Table 1 showed no
significant differences between the 2 treatment groups. The
mean age of study group was 65 years; 73% were male; and
17% had diabetes mellitus. The indication was stable angina
pectoris in three fourths of the patients and unstable angina
pectoris in one fourth of the patients. The use of aspirin,
clopidogrel, glycoprotein IIb/IIIa inhibitors, and bivalirudin
was similar in both groups.
Procedural and Lesion Characteristics
Details on procedural and lesion characteristics for the 2
groups are reported in Table 2. In the FKBD group, the target
bifurcation lesion was located in the left anterior descending
artery in 76% of patients compared with 67% of the no-
FKBD group (P0.03), whereas 12% in the FKBD group
had a treatment of the circumflex artery compared with 21%
Table 1. Baseline Clinical Characteristics
No FKBD
(n239)
FKBD
(n238) P
Age, y 64.210 65.210 0.25
Male, n (%) 173 (72.4) 174 (73.1) 0.91
Current smoker, n (%) 55 (22.6) 48 (20.3) 0.57
Hypercholesterolemia, n (%) 201 (84.1) 198 (83.2) 0.80
Hypertension, n (%) 158 (66.1) 145 (61.3) 0.29
Diabetes mellitus, n (%) 38 (15.9) 43 (17.7) 0.62
Family history, n (%) 146 (61.1) 133 (56.4) 0.30
Prior PCI, n (%) 74 (31.0) 57 (24.4) 0.12
Prior CABG, n (%) 5 (1.7) 7 (2.9) 0.38
CCS class 2 angina, n (%) 233 (97.5) 232 (97.4) 1.00
Indication, n (%)
Stable angina pectoris 177 (74.1) 177 (74.4) 1.00
Unstable angina pectoris 61 (25.6) 60 (25.2) 0.91
Silent ischemia 1 (0.4) 1 (0.4) 1.00
Antiplatelet therapy, n (%)
Aspirin 238 (99.6) 238 (100) 1.00
Clopidogrel 236 (98.7) 236 (99.2) 1.00
GP IIb/IIIa inhibitors 69 (28.9) 69 (29.1) 1.00
Bivalirudin 50 (20.9) 62 (26.2) 0.19
CABG indicates coronary artery bypass graft surgery; GP, glycoprotein
receptor. Values are mean SD when appropriate.
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in the no-FKBD group. The left main bifurcation was treated
in 8% of the patients. According to the Medina classifica-
tion,10 a “true bifurcation” lesion (Medina 1,1,1; 1,0,1; 0,1,1)
was observed in 50% of the patients by operator assessment.
The average vessel sizes, as evaluated by the operator, were
3.4 mm in the proximal MV and 2.7 mm in the SB, with
lesion lengths of 17.5 and 3.5 mm, respectively. The SB was
predilated in 29.0% and 27.6% (P0.76) in the FKBD and
the no-FKBD groups, respectively. The SB had a single
balloon dilatation through the MV stent in 33.3% of the
FKBD group and in 1.3% of the no-FKBD group
(P0.0001). Kissing balloon dilatation was performed after
MV stenting in 97.1% of the FKBD group and 0.8% of the
no-FKBD group. Procedure duration, fluoroscopic time, and
contrast media volume were significantly lower in the no-
FKBD group. Procedural success was similar in both groups.
Clinical Outcome
Clinical follow-up data at 6 months were available in all
patients, and the primary composite end point of 6-month
MACEs (cardiac death, nonprocedure-related index lesion
MI, TLR, definite stent thrombosis) is shown in Figure 2. The
6-month MACE rate was 2.1% in the FKBD and 2.5%
(P1.00) in the no-FKBD group. The individual end-point
rates of the components of MACE by 6 months (Table 3)
showed no differences between the 2 groups. The proportion
of CCS angina class 2 was similar in the study groups
before (97.4% versus 97.5%; P1.00; Table 1) and 6 months
after PCI (11.7% versus 12.0%; P1.00; Table 3).
Procedure-Related Elevation of Biomarkers
Procedure-related biomarker release was evaluated in 350
patients (175 in each group). Significant marker elevation
was observed in 6.3% of patients in both study groups.
Quantitative Coronary Angiography Analysis
A total of 374 patients were scheduled for 8-month angio-
graphic follow-up, and a complete angiographic data set was
available in 326 patients (87%). The results of the quantita-
tive coronary analysis are shown in Table 4. The reference
vessel diameters of the MV and SB at baseline, after stenting,
and at follow-up were similar in both groups. The minimal
luminal diameter of the SB tended to be larger in the FKBD
group at follow-up (1.740.48 versus 1.630.59 mm;
P0.06). At follow-up, the percentage of binary (re)stenosis
(diameter stenosis 50%) in the entire bifurcation lesion
(MV and SB) was 11.0% in the FKBD and 17.3% in the
no-FKBD group (P0.11). In the in-segment MV, restenosis
occurred in 3.1% and 2.5% (P0.68) in the FKBD and
no-FKBD groups, respectively. In the SB segment, the rates
were 7.9% versus 15.4% (P0.039), respectively. No pa-
tients in the FKBD group had a 75% diameter SB binary
Table 2. Procedural Characteristics
No FKBD
n239
FKBD
n238 P
LVEF, % 5910 5811 0.44
Lesion location, n (%)
Left anterior descending artery 160 (66.9) 182 (76.5) 0.03
Circumflex artery 51 (21.3) 28 (11.8) 0.01
Right coronary artery 13 (5.4) 9 (3.8) 0.51
Left main stem 17 (7.1) 19 (8.0) 0.73
True bifurcation lesion (Medina
1,1,1; 1.0.1; 0,1,1), n (%)*
117 (49.0) 129 (50.8) 0.71
Mean lesion length, mm*
MV 17.710.2 17.38.6 0.58
SB 3.64.2 3.43.9 0.62
MV mean stent length, mm* 22.910.5 23.611.1 0.50
Proximal reference diameter, mm*
MV 3.40.4 3.40.6 0.58
SB 2.70.4 2.60.3 0.05
MV stented, n (%) 238 (99.6) 238 (100) 1.00
SB stented, n (%) 0 (0) 3 (1.3) 0.12
SB dilatation through MV stent, n (%) 3 (1.3) 79 (33.3) 0.0001
FKBD, n (%) 2 (0.8) 231 (97.1) 0.0001
SB dilatation through MV stent or
FKBD, n (%)
4 (1.7) 231 (97.1) 0.0001
Treatment successful, n (%)† 236 (98.7) 236 (99.2) 1.00
Procedure time, min 4722 6128 0.0001
Fluoroscopy time, min 1110 1612 0.0001
Contrast volume, mL 20092 23597 0.0001
LVEF indicates left ventricular ejection fraction. Values are meanSD when
appropriate.
*By visual estimate.
†Residual stenosis 30% of MV and Thrombolysis in Myocardial Infarction
grade 3 flow in SB.
100
96
98
92
94
% P=1.0
90
0 5 10 15 20 25
Weeks
No-FKBD FKBD
Figure 2. Kaplan-Meier curves for MACE-free survival (cardiac
death, non–procedure-related index lesion MI, TLR, definite
stent thrombosis) in the FKBD and no-FKBD groups during the
6-month of follow-up.
Table 3. Individual Components of MACEs and Clinical
Outcomes at 6 Months
No FKBD (n239),
n (%)
FKBD (n238),
n (%) P
Noncardiac death 0 (0) 1 (0.4) 0.49
Cardiac death 0 (0) 2 (0.8) 0.24
Index lesion MI* 3 (1.3) 1 (0.4) 0.62
TLR 4 (1.7) 3 (1.3) 1.00
CCS class 2 angina 29 (12.0) 28 (11.7) 1.00
Stent thrombosis 1 (0.4) 1 (0.4) 1.00
The 2 test was used.
*Not procedure related.
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(re)stenosis compared with 4 patients (2.5%) in the no-FKBD
group (P0.06). Late lumen loss was similar both in the MV
segments and in the SB between treatment groups.
True Versus Nontrue Bifurcation
Subgroup Analysis
A total of 239 patients (50.1%) had a true bifurcation lesion
according to the Medina classification as assessed by the
operator. In this group, the 6-month MACE rates were 1.7%
and 2.5% (P0.68) and TLR rates were 0.8% and 1.7%
(P0.62) in the FKBD and no-FKBD groups, respectively. In
patients with nontrue bifurcations, the 6-month MACE rates
were 2.6% and 2.5% (P1.00) and TLR rates were 1.7% and
1.7% (P1.00) in the FKBD and no-FKBD groups, respec-
tively. Quantitative coronary analysis was available for 172
patients in the true bifurcation and in 154 in the nontrue
bifurcation subgroups. In the true bifurcation subgroup, angio-
graphic SB results were improved by FKBD (SB minimal
luminal diameter: 1.71*0.42 versus 1.50*0.53, P0.005; SB
diameter stenosis: 25*14 versus 32*21, P0.009; and SB binary
(re)stenosis: n7 [7.6%] versus n16 [20.0%], P0.024).
Angiographic outcome was not improved by FKBD in the
non-true bifurcation subgroup (Table 5).
Discussion
Our trial demonstrates that a simple MV stenting technique
without FKBD provides excellent clinical results that are
similar to those of the more complex strategy of MV stenting
with FKBD in patients with coronary bifurcation lesions. At
the 8-month angiographic follow-up, there was no significant
Table 5. True Versus Nontrue Bifurcation Subgroup Comparison: 8-Month Angiographic Follow-Up
Variable
True Bifurcation Subgroup Nontrue Bifurcation Subgroup
FKBD (n92) No FKBD (n80) P FKBD (n72) No FKBD (n82) P
In-segment MV
DS, % 2215 2215 0.85 2214 2112 0.90
50% DS, n (%) 3 (3.8) 2 (2.2) 0.67 3 (4.2) 1 (1.2) 0.34
Ostial 5 mm of the SB
MLD, mm 1.710.42 1.500.53 0.005 1.790.54 1.770.61 0.79
DS, % 2514 3221 0.009 2315 2719 0.21
50% DS, n (%) 7 (7.6) 16 (20) 0.024 6 (8.3) 9 (11) 0.79
DS indicates diameter stenosis; MLD, minimal luminal diameter. The Fisher exact test, 2 test, or independent-samples t test was used.
Table 4. Results of Quantitative Angiography in the 3 Bifurcation Segments
Variable
Proximal MV Distal MV SB
FKBD
(n164)
No FKBD
(n162) P
FKBD
(n164)
No FKBD
(n162) P
FKBD
(n164)
No FKBD
(n162) P
In-stent* minimal luminal diameter, mm
Before 1.390.57 1.430.63 0.54 1.470.57 1.420.57 0.39 1.590.56 1.540.60 0.65
After 2.700.44 2.640.45 0.16 2.430.41 2.440.40 0.88 1.600.46 1.540.53 0.22
Follow-up 2.760.54 2.650.56 0.06 2.480.49 2.420.53 0.30 1.740.48 1.630.59 0.06
In-stent* reference diameter, mm
Before 2.780.58 2.830.59 0.51 2.490.57 2.500.57 0.87 2.310.46 2.350.75 0.59
After 3.060.45 3.000.41 0.25 2.700.41 2.690.39 0.77 2.260.49 2.240.51 0.81
Follow-up 3.160.48 3.110.47 0.27 2.790.42 2.770.42 0.65 2.320.51 2.330.53 0.80
In-stent* diameter stenosis, %
Before 4921 4822 0.80 4020 4322 0.25 3120 3320 0.43
After 128 1210 0.49 109 99 0.47 2817 3119 0.12
Follow-up 1213 1513 0.06 1112 1313 0.18 2515 3020 0.009
In-stent* late lumen loss, mm 0.060.51 0.010.53 0.42 0.050.50 0.020.47 0.23 0.130.42 0.100.46 0.52
Edge minimal luminal diameter, mm
After 2.920.62 2.880.57 0.60 2.060.46 2.100.48 0.47
Follow-up 2.970.66 2.980.60 0.86 2.160.47 2.230.47 0.23
Restenosis, n (%)
In-stent* 3 (1.8) 3 (1.9) 1.00 2 (1.2) 3 (1.9) 1.00 13 (7.9) 25 (15.4) 0.039
Edge 2 (1.2) 0 (0) 0.50 2 (1.2) 0 (0) 0.50
Restenosis was defined as 50% diameter stenosis at the 8-month follow-up. The Fisher exact test, 2 test, or independent-samples t test was used.
*In-stent segments included the stented areas of the MV or the first 5 mm of the SB.
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difference in the binary (re)stenosis rate of the entire bifur-
cation lesion (MV plus SB) in the 2 treatment arms, but the
rate of SB (re)stenosis was increased in the no-FKBD group,
primarily as a result of increased (re)stenosis in true bifurca-
tion lesions treated without FKBD.
The optimal stenting technique for bifurcation lesions has
been debated, and several techniques using either 1 or 2 stents
have been introduced.11,12 The available data indicate that
most patients can be treated safely and effectively with a
provisional SB stenting strategy. However, it is not known
whether the MV stent should always be opened at the SB
ostium by SB rewiring through the MV stent and subsequent
balloon dilatation. It might be expected that SB blood flow
would improve after opening the MV stent at the SB ostium.
On the other hand, distortion of the MV stent might be a
concern. Meticulous bench testing has shown that stent
deformation is consistently seen after opening of a stent, but
this deformation can be corrected by FKBD.13,14 Therefore,
the present study compared FKBD and no FKBD to investi-
gate both the clinical and angiographic effects of routine
opening of the MV stent struts at the SB ostium in bifurcation
lesions treated with MV stenting.
Stringent criteria for SB stenting were applied in our study.
The crossover rate was low, allowing a true comparison of the
2 study groups. Thus, any SB dilatation was performed in
only 1.7% of the patients in the no-FKBD group, and the
crossover rate from no-FKBD to FKBD strategy was only
0.8%. Furthermore, no patients in the no-FKBD group and
1.3% of patients in the FKBD group received a SB stent.
Therefore, the treatment principles used in our study seem
applicable to almost all bifurcation lesions with normal SB
blood flow after MV stenting.
Our results are consistent with a recent study that random-
ized 110 patients to mandatory kissing balloon inflation or to
provisional kissing after stenting.15 However, only 73% of the
patients in that study compared with 97.1% in our study
underwent kissing balloon dilatation in the FKBD arm, and
17.9% of the patients had stenting of the SB in the FKBD
arm15 compared with 1.3% in the present study.
Clinical Outcomes
Both study groups had excellent clinical results. Mortality
and incidence of MI were low and comparable to recent
randomized bifurcation studies using drug-eluting stents that
did not include procedure-related MI4 and slightly lower than
in studies that included procedure-related MI.5–7 The rate of
definite stent thrombosis was 0.4% in the 2 groups. Thus, MV
stenting without FKBD could be performed without increas-
ing the risk of stent thrombosis within the observation period.
A considerable longer follow-up is needed to obtain a reliable
assessment of the risk of stent thrombosis. It has been
suggested that postdilatation would facilitate subsequent SB
access.14 We found that the need for TLR was 2% after 6
months, indicating that the need for subsequent SB access
was low.
An important observation of the present study relates to the
favorable results relative to the occurrence of angina pectoris.
The majority of patients had severe angina pectoris at
baseline. At the 6-month follow up, symptom relief was
substantial and similar in both groups.
Quantitative Coronary Angiography Analysis
The 8-month quantitative coronary analysis revealed excel-
lent results in the MV segment and improved angiographic
results in the SB in the FKBD group. The follow-up percent
diameter stenosis and the incidence of (re)stenosis in the SB
were higher in the no-FKBD arm compared with patients
assigned to FKBD. This difference was not due to greater late
lumen loss, which was similar in both treatment arms.
Significant residual SB stenosis potentially causes significant
angina pectoris and subsequent TLR. However, in our study,
CCS class 2 or higher angina occurred with similar frequency
during follow-up in both treatment arms. Furthermore, the
need for clinical driven TLR in the patients included in the
angiographic substudy was only 0.6% and 1.9% in the FKBD
and no-FKBD groups, respectively. Thus, the clinical rele-
vance of angiographic SB (re)stenosis, although assessed 2
months later, was negligible in the present study. Accord-
ingly, the assessment of SB stenosis with fractional flow
reserve found that this functional assessment correlated only
weakly with angiography.16
True and Nontrue Bifurcation Lesions
Clinical end point rates in true and nontrue bifurcation lesions
were low. Hence, possible differences in the clinical outcome
between the 2 treatment groups were not detectable. In the
true bifurcation lesion subgroup, FKBD reduced SB (re)ste-
nosis significantly, an effect that might become clinically
relevant and justify the more complex FKBD procedure. In
the subgroup of nontrue bifurcation lesions, no difference in
angiographic outcome between FKBD and no-FKBD was
found.
Study Limitations
The open-label design with operators and patients being aware
of the treatment assignment is a limitation of the study. It is,
however, impossible to blind the operator in this type of study.
Data completeness and consistency were audited centrally at the
PCI Research Unit, Aarhus University Hospital, Skejby, but
there were no onsite audits. The lack of onsite study monitoring
might have led to an underreporting of events. MACEs were
adjudicated by a blinded event committee, which should reduce
the bias of the open-label design.
Mortality and incidence of MI were low in our study, and
procedure-related MI was excluded from our primary end
point. Hence, comparison to results from other bifurcation
studies should be made cautiously. Given the observed
clinical event rates, the study was underpowered. However,
considering the low event rates, a properly powered study
with a 6-month clinical follow-up is not realistic. Future
studies will have to focus on imaging or fractional flow
reserve end points or possibly longer-term follow-up.
Importantly, the average SB reference 2.33 mm by quan-
titative coronary analysis and 2.63 mm by visual estimation,
while the SB lesion length was 3.5 mm by visual estimation.
Furthermore, the prevalence of nontrue bifurcation lesions
according to the Medina classification was 50% in our study.
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Extrapolation of the results to all types of bifurcations,
especially to genuine bifurcation lesions with a large SB or
long SB lesions, should be done cautiously. Because the
clinical follow-up was restricted to 6 months, no conclusions
can be drawn about the long-term safety profile of either
treatment strategy.
Conclusions
In coronary bifurcation lesions, MV stenting with and without
FKBD was associated with favorable and similar 6-month
clinical outcomes. The simple no-FKBD procedure resulted
in reduced use of contrast media and shorter procedure and
fluoroscopy times. Angiographic SB outcome was improved
by FKBD, especially in patients with true bifurcation lesions.
In nontrue bifurcation lesions, no effect of FKBD was
detected by either clinical or angiographic end points. Long-
term safety data are needed.
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CLINICAL PERSPECTIVE
The 1-stent bifurcation stenting approach with stenting of the main vessel and optional side branch stenting using
drug-eluting stents is the preferred strategy to treat coronary bifurcation lesions. It is unknown whether a successful main
vessel stenting procedure should be finalized by a simultaneous kissing balloon dilatation (FKBD). In the present study,
477 patients with successful main vessel stenting were randomized to FKBD versus no FKBD. The 6-month rates of major
adverse cardiac events (cardiac death, non–procedure-related index lesion myocardial infarction, target lesion revascular-
ization, or stent thrombosis) were similar and low in the study groups. FKBD reduced angiographic side branch
(re)stenosis, especially in patients with true bifurcation lesions. The simple no-FKBD procedures resulted in reduced use
of contrast media and shorter procedure and fluoroscopy times. FKBD may be recommended in genuine bifurcation lesions
treated with main vessel stenting but may be avoided in bifurcations without side branch stenosis. Long-term data on stent
thrombosis are needed.
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